Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
No Thumbnail Available
Embargo End Date
ICR Authors
Authors
Boon, E
van der Graaf, WTA
Gelderblom, H
Tesselaar, MET
van Es, RJJ
Oosting, SF
de Bree, R
van Meerten, E
Hoeben, A
Smeele, LE
Willems, SM
Witjes, MJH
Buter, J
Baatenburg de Jong, RJ
Flucke, UE
Peer, PGM
Bovée, JVMG
Van Herpen, CML
van der Graaf, WTA
Gelderblom, H
Tesselaar, MET
van Es, RJJ
Oosting, SF
de Bree, R
van Meerten, E
Hoeben, A
Smeele, LE
Willems, SM
Witjes, MJH
Buter, J
Baatenburg de Jong, RJ
Flucke, UE
Peer, PGM
Bovée, JVMG
Van Herpen, CML
Document Type
Journal Article
Date
2017-01
Date Accepted
2016-06-24
Abstract
Background There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck.Methods All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed.Results We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively).Conclusion In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy. © 2016 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 39: 140-146, 2017.
Citation
Head & neck, 2017, 39 (1), pp. 140 - 146
Source Title
Publisher
ISSN
1043-3074
eISSN
1097-0347
Collections
Research Team
Clinical and Translational Sarcoma
